A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients who are 18F-DCFPyL prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naïve, and progressed on abiraterone (ARROW)

IRB/UVA Tracking #
21688
Contact
Julio Torres
Contact Email
Contact Phone
1.434.982.4110
Phase
II
Primary purpose
Treatment
Cancer PI
Robert Dreicer
Status
OPEN TO ACCRUAL
Ages
Adult